Folates and prevention of disease

Abstract Research in the past decade has established that low or inadequate folate status may contribute to congenital malformations and the development of chronic disease in later life. Using an evidence based approach, there are clear guidelines for recommending folic acid supplementation or fortification in certain disease conditions but further proof of its efficacy is required in other circumstances. There is conclusive evidence that maternal periconceptional supplementation with folic acid prevents the majority of NTDs, probably by overcoming one or more genetically inherited metabolic blocks in folate dependent enzymes. Public health efforts to advise women to increase their folate intake have not been successful. As a result, the U.S. government passed legislation to have all flour fortified with folic acid. This intervention has had a dramatic effect on folate status in the U.S. To date, countries of the EU have not adopted mandatory fortification policies. The amino acid homocysteine is an essential intermediate in folate metabolism. Substantial evidence indicates that elevated plasma homocysteine is an independent risk factor for heart disease and stroke. Plasma homocysteine levels can be reduced by folic acid supplements. A food fortification policy would probably be an effective population strategy to reduce plasma homocysteine. However, many experts believe that this would be premature without first showing that such reduction would cause a decrease in the prevalence of cardiovascular disease. The contribution of folate to cancer risk is not well defined although there is reasonable evidence to implicate low folate status in the specific case of colorectal cancer. In particular, long-term folic acid supplementation may reduce risk of colorectal cancer substantially. Various mental disorders including Alzheimer's Disease have been associated with low folate status or elevated plasma homocysteine. While it is hard to determine if this is cause or effect, there is little doubt that if it were true then low dose folic acid intervention would be highly effective.

[1]  D. Weir,et al.  Folic acid metabolism and mechanisms of neural tube defects. , 2007, Ciba Foundation symposium.

[2]  S. Yusuf,et al.  Homocyst(e)ine and Cardiovascular Disease: A Critical Review of the Epidemiologic Evidence , 1999, Annals of Internal Medicine.

[3]  P. Wilson,et al.  The effect of folic acid fortification on plasma folate and total homocysteine concentrations. , 1999, The New England journal of medicine.

[4]  J. Scott,et al.  Folate and vitamin B12 , 1999, Proceedings of the Nutrition Society.

[5]  D. Shields,et al.  The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: An evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. , 1999, American journal of human genetics.

[6]  D. Weir,et al.  Homocysteine as a risk factor for cardiovascular and related disease: nutritional implications , 1998, Nutrition Research Reviews.

[7]  R Clarke,et al.  Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. , 1998, Archives of neurology.

[8]  F. Speizer,et al.  Multivitamin Use, Folate, and Colon Cancer in Women in the Nurses' Health Study , 1998, Annals of Internal Medicine.

[9]  J. Clegg,et al.  Worldwide distribution of a common methylenetetrahydrofolate reductase mutation. , 1998, American journal of human genetics.

[10]  H. Blom,et al.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.

[11]  S. Daly,et al.  Minimum effective dose of folic acid for food fortification to prevent neural-tube defects , 1997, The Lancet.

[12]  B. Ames,et al.  Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: implications for cancer and neuronal damage. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. McNulty,et al.  Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects , 1996, The Lancet.

[14]  D. Weir,et al.  Folate levels and neural tube defects. Implications for prevention. , 1995, JAMA.

[15]  S. Ebrahim,et al.  Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men , 1995, The Lancet.

[16]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[17]  C. Bower,et al.  Folate and neural tube defects. , 1995, Nutrition reviews.

[18]  R. D'Agostino,et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. , 1995, The New England journal of medicine.

[19]  D. Weir,et al.  Prevention of neural tube defects with folic acid a success but... , 1994, QJM : monthly journal of the Association of Physicians.

[20]  M. Levene,et al.  Prevention of neural-tube defects , 1993, The Lancet.

[21]  L. Chambless,et al.  Carotid artery intimal-medial wall thickening and plasma homocyst(e)ine in asymptomatic adults. The Atherosclerosis Risk in Communities Study. , 1993, Circulation.

[22]  M. J. Seller,et al.  Epidemiology and Control of Neural Tube Defects , 1993 .

[23]  A. Czeizel,et al.  Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. , 1992, The New England journal of medicine.

[24]  J. Mulinare,et al.  Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. , 1992, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[25]  I. Graham Homocysteine as a risk factor for cardiovascular disease. , 1991, Trends in cardiovascular medicine.

[26]  M. Gnant,et al.  Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study , 1991, The Lancet.

[27]  H. Dolk Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. EUROCAT Working Group. , 1991, Journal of epidemiology and community health.

[28]  A. Read,et al.  FURTHER EXPERIENCE OF VITAMIN SUPPLEMENTATION FOR PREVENTION OF NEURAL TUBE DEFECT RECURRENCES , 1983, The Lancet.

[29]  K. Laurence,et al.  Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. , 1981, British medical journal.

[30]  J. Elwood,et al.  POSSIBLE PREVENTION OF NEURAL-TUBE DEFECTS BY PERICONCEPTIONAL VITAMIN SUPPLEMENTATION , 1980, The Lancet.

[31]  K. Mccully Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. , 1969, The American journal of pathology.

[32]  J. Mason,et al.  Folate and carcinogenesis: an integrated scheme. , 2000, The Journal of nutrition.

[33]  D. Weir,et al.  Folate/vitamin B12 inter-relationships. , 1994, Essays in biochemistry.

[34]  E. Garne Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986 , 2022 .